Technology area: Biotechnology & Pharmaceuticals
14 pending office actions • 8 art units • 13 examiners • 0 of 14 (0%) have an AI response strategy ready • 9 patents granted in the last 365 days
Beam Therapeutics Inc. has 14 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 13 distinct examiners across 8 distinct art units, indicating that most files have separate examiner relationships while some technical grouping remains.
YU, DAVID TUYANG is the busiest examiner, with 2 pending matters. The limited assignment supports examiner-specific preparation, but the broader distribution calls for coordinated portfolio tracking and consistency in technical and claim-position decisions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (7%) |
| §103 only | 3 (21%) |
| §112 only | 1 (7%) |
| Double-patenting + other | 4 (29%) |
| Multi-statute (no §101) | 4 (29%) |
| No statute on record | 1 (7%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| YU, DAVID TUYANG | 2 | 100.0% | +0.0% |
| DACE DENITO, ALEXANDRA GERALDINE | 1 | 54.5% | +32.6% |
| LEE, JAE W | 1 | 65.6% | +38.5% |
| BAEK, BONG-SOOK | 1 | 41.6% | +69.9% |
| WELLS, LAUREN QUINLAN | 1 | 49.4% | +59.7% |
| WARD, AARON DUREL | 1 | 0.0% | +0.0% |
| HIBBERT, CATHERINE S | 1 | 58.8% | +48.6% |
| SULLIVAN, STEPHANIE LAUREN | 1 | 57.1% | +38.1% |
| NOAKES, SUZANNE MARIE | 1 | 73.4% | +18.3% |
| DHAR, MATASHA | 1 | 43.5% | +44.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18807580 | METHODS OF SUBSTITUTING PATHOGENIC AMINO ACIDS USING PROGRAMMABLE BASE EDITOR SYSTEMS | LEE, JAE W | — |
| 18746791 | NANOMATERIALS COMPRISING TETRAVALENT LIPID COMPOUNDS | BAEK, BONG-SOOK | — |
| 18441740 | PERSISTENT ALLOGENEIC MODIFIED IMMUNE CELLS AND METHODS OF USE THEREOF | WARD, AARON DUREL | — |
| 18519954 | COMPOSITIONS AND METHODS FOR THE SELF-INACTIVATION OF BASE EDITORS | YU, DAVID TUYANG | — |
| 17610119 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B | GIBBS, TERRA C | — |
| 17265440 | MULTI-EFFECTOR NUCLEOBASE EDITORS AND METHODS OF USING SAME TO MODIFY A NUCLEIC ACID TARGET SEQUENCE | YU, DAVID TUYANG | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18460178 | USES OF ADENOSINE BASE EDITORS | NOAKES, SUZANNE MARIE | 42d overdue |
| 19649581 | METHODS AND COMPOSITIONS FOR TREATING ALPHA-1 ANTITRYPSIN DEFICIENCY | DACE DENITO, ALEXANDRA GERALDINE | — |
| 18807580 | METHODS OF SUBSTITUTING PATHOGENIC AMINO ACIDS USING PROGRAMMABLE BASE EDITOR SYSTEMS | LEE, JAE W | — |
| 18746791 | NANOMATERIALS COMPRISING TETRAVALENT LIPID COMPOUNDS | BAEK, BONG-SOOK | — |
| 18746787 | NANOMATERIALS COMPRISING DISULFIDES | WELLS, LAUREN QUINLAN | — |
| 18515118 | BASE EDITING OF TRANSTHYRETIN GENE | HIBBERT, CATHERINE S | — |
| 18507980 | COMPOSITIONS AND METHODS FOR TREATING TRANSTHYRETIN AMYLOIDOSIS | SULLIVAN, STEPHANIE LAUREN | — |
| 17940636 | VIRAL GUIDE RNA DELIVERY | DHAR, MATASHA | — |
| Art Unit | Apps |
|---|---|
| 1635 | 4 |
| 1636 | 2 |
| 1656 | 2 |
| 1611 | 1 |
| 1658 | 1 |
| 1632 | 1 |
| 1600 | 1 |
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19649581 | METHODS AND COMPOSITIONS FOR TREATING ALPHA-1 ANTITRYPSIN DEFICIENCY | DACE DENITO, ALEXANDRA GERALDINE | 1636 | §103 | Non-Final OA | — | Pending | Apr 16, 2026 |
| 18807580 | METHODS OF SUBSTITUTING PATHOGENIC AMINO ACIDS USING PROGRAMMABLE BASE EDITOR SYSTEMS | LEE, JAE W | 1656 | §103§112 | Non-Final OA | — | Pending | Aug 16, 2024 |
| 18746791 | NANOMATERIALS COMPRISING TETRAVALENT LIPID COMPOUNDS | BAEK, BONG-SOOK | 1611 | §102§112 | Non-Final OA | — | Pending | Jun 18, 2024 |
| 18746787 | NANOMATERIALS COMPRISING DISULFIDES | WELLS, LAUREN QUINLAN | — | §112 | Non-Final OA | — | Pending | Jun 18, 2024 |
| 18441740 | PERSISTENT ALLOGENEIC MODIFIED IMMUNE CELLS AND METHODS OF USE THEREOF | WARD, AARON DUREL | 1636 | §102§103§112DP | Non-Final OA | — | Pending | Feb 14, 2024 |
| 18519954 | COMPOSITIONS AND METHODS FOR THE SELF-INACTIVATION OF BASE EDITORS | YU, DAVID TUYANG | 1635 | §101§103 | Non-Final OA | — | Pending | Nov 27, 2023 |
| 18515118 | BASE EDITING OF TRANSTHYRETIN GENE | HIBBERT, CATHERINE S | 1658 | §102§103DP | Non-Final OA | — | Pending | Nov 20, 2023 |
| 18507980 | COMPOSITIONS AND METHODS FOR TREATING TRANSTHYRETIN AMYLOIDOSIS | SULLIVAN, STEPHANIE LAUREN | 1635 | §103§112DP | Non-Final OA | — | Pending | Nov 13, 2023 |
| 18460178 | USES OF ADENOSINE BASE EDITORS | NOAKES, SUZANNE MARIE | 1656 | Other | Non-Final OA | 42d overdue | Pending | Sep 01, 2023 |
| 17940636 | VIRAL GUIDE RNA DELIVERY | DHAR, MATASHA | 1632 | §103 | Final Rejection | — | Pending | Sep 08, 2022 |
| 17638757 | COMPOSITIONS AND METHODS FOR EDITING A MUTATION TO PERMIT TRANSCRIPTION OR EXPRESSION | KONOPKA, CATHERINE ANNE | 1635 | §103§112DP | Final Rejection | — | Pending | Feb 25, 2022 |
| 17610119 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B | GIBBS, TERRA C | 1635 | §103§112 | Final Rejection | — | Pending | Nov 09, 2021 |
| 17265440 | MULTI-EFFECTOR NUCLEOBASE EDITORS AND METHODS OF USING SAME TO MODIFY A NUCLEIC ACID TARGET SEQUENCE | YU, DAVID TUYANG | 1600 | §103§112 | Final Rejection | — | Pending | Feb 02, 2021 |
| 17054393 | METHODS OF SUPPRESSING PATHOGENIC MUTATIONS USING PROGRAMMABLE BASE EDITOR SYSTEMS | POPA, ILEANA | 1633 | §103 | Final Rejection | — | Pending | Nov 10, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBeam Therapeutics Inc. has 14 pending office actions as of October 2026, spread across 8 art units and 13 examiners.
David Tuyang Yu has the most, with 2 of Beam Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
